CelVivo CSO is Plenary Speaker at 12th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry CelVivo's CSO, Dr. Krzysztof Wrzesinski, delivered the plenary speech at the 12th World Congress on Pharmaceutical Sciences and Innovations in Pharma Industry, (February 26- 27, 2018 London). Attendees from over 70 companies and institutions heard speakers discuss newest approaches used for drug discovery and development, as well as strategies for creation of new drugs based on natural medicine compounds. Dr. Wrzesinski’s talk was entitled "Active 3D environment: a key to stable, reproducible, mimetic tissues". The talk presented advantages of using active 3D spheroid/organoid cultures for drug candidate screening.
Dr. Wrzesinski was honoured to be the judge of the conference young scientist poster session. The conference poster prize was awarded to PhD student Valeria Chiaula representing Danish Polymer Centre, Danish Technical University, Copenhagen, for her poster "Advanced wound care adhesives with new functional properties"- congratulation to Valeria.
CelVivo's BioArray Matrix drive achieves 'CE marking' status
The term CE marking on a product is a manufacturer's declaration that the product complies with all the essential requirements of the relevant European health, safety and environmental protection legislation ('European Standards' or 'Harmonization Documents').
"This is a milestone achievement for us" says CEO Dr. Stephen Fey. "This will allow us to distribute our equipment freely within the EU, EFTA and EEA countries. It is a strong signal that our BioArray Matrix is a reliable and powerful new instrument for the 3D cell culture laboratory, and brings an exciting future to us and our collaborators."
The founding manuscript "Determination of Drug Toxicity Using 3D Spheroids Constructed From an Immortal Human Hepatocyte Cell Line" has now been cited 48 times according to the Web of Science.
Link to manuscript:
Link to list of citing manuscripts:
Completion of Innobooster Development Project
CelVivo has reported the successful, on time, completion of the Innobooster development project to the Danish Innovation Fund. The BioArray Matrix drive met all design specifications. The unit now logs all user entries and its own performance and makes this data available as documentation of operation performance (needed for example for Regulatory Authorities).
Cell Guidance and Fitness
CelVivo's CSO, Dr. Krzysztof Wrzesinski, has been selected as a Danish representative for the managing committee of the COST Action “In vitro 3-D total cell guidance and fitness” (CellFit) CA16119. This is a European Union funded network aimed at developing tools to exploit environmental cues, mechano-transduction and 3D culture to stably maintain or address cells towards a specific fate. The goal of this network is to reduce the discrepancy between data obtained in vitro and in vivo by refining our present understanding of the cell environment, in order to create reliable in vitro models that may replace/reduce the use of animals.
The kick off meeting of the CellFit COST action was held in Brussels, Belgium on 16 March 2017. Dr. Wrzesinski was one of the 60 persons from 31 European countries represented.
More details about the CellFit COST action activities can be found under following links:
BioArray Matrix System Upgrade
The BioArray Matrix (BAM) systems operating at the Centre of Excellence for Pharmaceutical Sciences, North-West University; Potchefstroom South Africa and at Diabetes Discovery Platform; South African Medical Research Council; Cape Town have been upgraded to BAM system version 4.6 which include active data logging system. Prof. Hamman, Dir Johan Louw and their groups acted as independent β-test sites for the new BAM drive.
Antibiotic resistance is an increasing menace facing our society. This is not only true for a country like Denmark where pig farming is an important export, but also to countries where the population is at risk from tuberculosis or any country that relies on antibiotics.
CelVivo's CEO, Stephen J. Fey was co-organiser of the open symposium "New Possibilities for Treatment of Multiresistant Infections with Non-antibiotics” which was held in the historical "Fællessalen" at Christiansborg – the seat of the Danish Parliament. The meeting was hosted by Jane Heitmann (Health spokesperson for Venstre) and Flemming Møller (MP) and moderated by Peter Hyldgård (Journalist, Videnskab.dk). Dr. Fey gave the presentation "Breaking resistance development using molecules 'dancing' in Fibronacci patterns" and described the opportunity to test toxicity of non-antibiotics in human mimetic systems.
Danish Innovation Fund
The Danish Innovation Fund has awarded CelVivo Innobooster support to further develop its proprietary BioArray Matrix (BAM) drive. The developments will extend the performance of the BAM drive, captures and logs additional performance data and make it available to the user.
EMBO Symposium on Organoids
CelVivo was well represented at the recent highly successful EMBO | EMBL Symposium "Organoids – Modelling Organ Development and Disease in 3D Culture" (Heidelberg, Germany (12-15 October 2016).
CelVivo's CSO, Dr. Krzysztof Wrzesinski presented a poster and a flash presentation "Mimicking the feeding-fasting cycle using microgravity 3D spheroids"
CelVivo's CEO, Dr. Stephen J. Fey presented a poster entitled "Epigenetic Markers and Histone Clipping are Reproduced in Microgravity 3D Spheroids". Both sets of data were obtained using the bioreactors and BioArray Matrix drive from CelVivo.
Natural Products Chemistry to Drug Discovery
CelVivo's CEO, Dr. Stephen J. Fey is a Danish representative for participating in the CMST COST Action CM1407 "Challenging organic syntheses inspired by nature – from natural products chemistry to drug discovery".
The utility of the 3D cell culture in the BioArray Matrix drive system was illustrated at the second meeting of the CM1407, held in Madrid from the 3rd to the 6th April in a presentation entitled: "Active 3D spheroids recapitulate epigenetic marking and can be used to reveal novel signaling pathways".
Toxicological and Efficacy Studies
CelVivo's CEO, Dr. Stephen J. Fey is a Danish representative for participating in the CMST COST Action CM1407 “Challenging organic syntheses inspired by nature – from natural products chemistry to drug discovery”.
CelVivo's BAM system was potential for toxicological and efficacy studies was described during the 3rd meeting of CM1407, held in Krakow, Poland from the 1st – 4th March in a presentation entitled “Testing natural products using an in-vivo-mimetic system”.
If you wish to add your name to our mailing list and be the first to receive news and updates, click here.